Results 21 to 30 of about 3,645,426 (307)

Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature

BMC Gastroenterology, 2021
Background Colorectal cancer (CRC) is the third most prevalent cancer worldwide and poses a serious challenge for clinicians. Previous studies have shown promising results in patients with Microsatellite Stable microsatellite-stable CRC refractory to ...
Yong Zhang, Fang Zhang, Lingdi Zhao, Xiaomin Fu, Yiman Shang, Quanli Gao   +5 more
doaj   +1 more source

Ferroptosis in cancer and cancer immunotherapy [PDF]

Cancer Communications, 2022
Abstract The hallmark of tumorigenesis is the successful circumvention of cell death regulation for achieving unlimited replication and immortality. Ferroptosis is a newly identified type of cell death dependent on lipid peroxidation which differs from classical programmed cell death in terms of morphology, physiology and biochemistry.
Lei Zhao, Xiaoxue Zhou, Feng Xie, Lei Zhang, Haiyan Yan, Jun Huang, Chong Zhang, Fangfang Zhou, Jun Chen, Long Zhang   +9 more
openaire   +3 more sources

Immunotherapy through the Lens of Non-Small Cell Lung Cancer

, 2023
Immunotherapy has revolutionised anti-cancer treatment in solid organ malignancies. Specifically, the discovery of CTLA-4 followed by PD-1 in the early 2000s led to the practice-changing clinical development of immune checkpoint inhibitors (ICI ...
Saoirse Flanagan, Ella Kearney, Catríona M. Dowling, David O’ Reilly, Robyn Stanley, Jarushka Naidoo   +5 more
core   +1 more source

Regulation of cell death in cancer - possible implications for immunotherapy [PDF]

, 2013
Since most anticancer therapies including immunotherapy trigger programmed cell death in cancer cells, defective cell death programs can lead to treatment resistance and tumor immune escape.
Simone Fulda, Simone eFulda, Fulda, Simone   +2 more
core   +1 more source

Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again

Genome Medicine, 2018
For at least 300 years the immune system has been targeted to improve human health. Decades of work advancing immunotherapies against infection and autoimmunity paved the way for the current explosion in cancer immunotherapies.
Samantha L. Bucktrout, Jeffrey A. Bluestone, Fred Ramsdell   +2 more
doaj   +1 more source

High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study

Frontiers in Immunology, 2022
Background and ObjectiveThe results of the CheckMate 025 trial established the status of nivolumab in the second-line treatment of metastatic renal cell carcinoma (mRCC), with an objective response rate (ORR) of 25% and a complete response (CR) rate of 1%
Lingdi Zhao, Tiepeng Li, Yongping Song, Yonghao Yang, Baozhen Ma, Yong Zhang, Yiman Shang, Benling Xu, Jindong Guo, Peng Qin, Lu Han, Xiaomin Fu, Hongwei Lin, Liang Liu, Xiubao Ren, Zibing Wang, Quanli Gao   +16 more
doaj   +1 more source

Immunotherapy: Review of the Existing Evidence and Challenges in Breast Cancer

, 2023
Breast cancer (BC) is a representative malignant tumor that affects women across the world, and it is the main cause of cancer-related deaths in women. Although a large number of treatment methods have been developed for BC in recent years, the results ...
Xiaoyi Zhang, Hongzhou Cai, Junying Zhang, Yun Hu, Fenglin Huang, Yan Li, Zhangcheng Yao, Hanyuan Liu, Huang, Fenglin, Liu, Hanyuan, Cai, Hongzhou, Yao, Zhangcheng, Hu, Yun, Zhang, Junying, Li, Yan, Zhang, Xiaoyi   +15 more
core   +1 more source

ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism

OncoImmunology, 2017
Immune evasion of tumors poses a major challenge for immunotherapy. For human papillomavirus (HPV)-induced malignancies, multiple immune evasion mechanisms have been described, including altered expression of antigen processing machinery (APM) components.
Alina Steinbach, Jan Winter, Miriam Reuschenbach, Renata Blatnik, Alexandra Klevenz, Miriam Bertrand, Stephanie Hoppe, Magnus von Knebel Doeberitz, Agnieszka K. Grabowska, Angelika B. Riemer   +9 more
doaj   +1 more source

Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer

Scientific Reports, 2021
Despite recent progress in therapeutic strategies, prognosis of metastatic triple-negative breast cancer (TNBC) remains dismal. Evidence suggests that the induction and activation of tumor-residing conventional type-1 dendritic cells (cDC1s) is critical ...
Toshihiro Yokoi, Takaaki Oba, Ryutaro Kajihara, Scott I. Abrams, Fumito Ito   +4 more
doaj   +1 more source

Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model

OncoImmunology, 2019
Therapeutic vaccination as a treatment option for HPV-induced cancers is actively pursued because the two HPV proteins E6 and E7 represent ideal targets for immunotherapy, as they are non-self and expressed in all tumor stages.
Sebastian Kruse, Marleen Büchler, Philipp Uhl, Max Sauter, Philipp Scherer, Tammy C.T. Lan, Samantha Zottnick, Alexandra Klevenz, Ruwen Yang, Frank Rösl, Walter Mier, Angelika B. Riemer   +11 more
doaj   +1 more source